Know Labs, Inc. focuses on the development and commercialization of proprietary technologies in the United States. Its technology uses spectroscopy to direct electromagnetic energy through a substance or material to capture a molecular signature. The company refers to its technology as Bio-RFID. The Bio-RFID technology can be integrated into various wearable, mobile, or bench-top form factors. Its first application of Bio-RFID technology is a product marketed as a glucose monitor that provide the user with real time information on their blood glucose levels. The company was formerly known as Visualant, Incorporated and changed its name to Know Labs, Inc. in May 2018. Know Labs, Inc. was founded in 1998 and is headquartered in Seattle, Washington.

Know Labs, Inc.

Know Labs uses non-invasive diagnostic technology to identify and measure a variety of molecules using radio waves.

Know Labs

Know Labs, Inc. | 2,947 followers on LinkedIn. Transforming Non-Invasive Medical Diagnostics | Know Labs is transforming non-invasive medical diagnostics. The proprietary technology platform uses radiofrequency (RF) dielectric spectroscopy and can be integrated into a variety of wearable, mobile, or bench-top form factors. The first application is a non-invasive continuous blood glucose monitoring device that will provide the user with real-time information on their blood glucose levels, assisting billions of people with diabetes and prediabetes to manage this medical condition.

Ron Erickson

Chief Financial Officer & Senior Vice President, Intellectual Property (IP), Know Labs (NYSE: KNW)

Peter Conley

Karmeen Kulkarni

CMO @Know Labs ($KNW) I Mama to Izzy I Ex-Oura, Dropbox, Electronic Arts I Brand Builder I Board Member

Jessica English

New update --> Our team is exploring a great growth opportunity. More to come soon. https://lnkd.in/gpixsQfD

Today, Know Labs announced the publication of our peer-reviewed study in the esteemed Diabetes Technology and Therapeutics Journal. The study demonstrates the accuracy of our proprietary radiofrequency (RF) dielectric sensor in classifying an individual’s glycemic status—serving as proof-of-concept for a novel, non-invasive screening device. We are incredibly proud of the team involved with producing these results and remain committed to developing accurate, affordable, and accessible solutions for the 500M+ people worldwide living with diabetes and the 240M+ people worldwide remaining undiagnosed. See the published article here: https://lnkd.in/gHch98X6

Today Know Labs led an interactive discussion during Friends For Life Orlando 2024 where we imagined a world with a no-needle CGM. Thank you Children With Diabetes for having us and for continuing to support our mission to deliver the first FDA-cleared non-invasive CGM to the marketplace. A very special thank-you to all those who participated in the discussion by sharing your stories, asking thoughtful questions, and helping us ensure we get it right. #FFLOrlando24

This article in CNET featured Know Labs as one company working to develop a truly no-needle device that can accurately measure blood glucose. The article covered our recent clinical results presentation at the American Diabetes Association 's 84th Scientific Sessions, the platform nature of our proprietary radiofrequency (RF) technology, and the impact non-invasive medical diagnostics could have on predictive health. Read the full article here: https://lnkd.in/gTsvcNtJ #medicaldevice #glucosemonitoring #CGM

Today we announced that we’ve been selected for an abstract poster presentation at the American Diabetes Association ’s (ADA) 84th Scientific Sessions in Orlando, Florida on Saturday, June 22, 2024 at 12:30 p.m. - 1:30 p.m. EDT. For those attending, Dr. Virend K. Somers of the Mayo Clinic will be presenting the abstract titled, “A New Machine Learning Model and Expanded Dataset for a Non-Invasive BGM.” These interim study results are the latest from our clinical research protocol involving participants with pre-diabetes and T2D, using venous blood as a comparative reference. The results demonstrate a stable MARD with more than twice as much data collected from 22 participants and a new machine learning model. See the full announcement here: https://lnkd.in/gRZqPWeX #ADASciSessions

We're excited to share that Know Labs, Inc. has joined the Wyss Diagnostic Accelerator (DxA)'s Industrial Participant Program(IPP). They are the twentieth IPP member, joining other companies with a range of diagnostically relevant expertise. The Wyss DxA IPP serves as a collaboration hub between healthcare testing companies, and the scientific and clinical community within the Wyss Institute, as well as our affiliated institutions and the broader Harvard ecosystem. https://bit.ly/3z0TWBw

Wyss Institute at Harvard University

Great event, lots of new connections! Thank you BIO International Convention .

Leo Trautwein

Today we announced that we've joined the renowned Industrial Participant Program of the Wyss Institute at Harvard University 's Diagnostics Accelerator. As a member, Know Labs joins other leaders dedicated to accelerating the development of disruptive, innovative solutions that address urgent and unmet clinical needs. We'll contribute experience in developing novel radiofrequency (RF) dielectric sensor technology for applications in non-invasive blood glucose monitoring for diabetes management, as well as for broader medical diagnostic applications. See more in a release here: https://lnkd.in/gbhtq_5w

It was my pleasure to show Know Labs, Inc. progress at Hospitalar 2024, as part of the State of Washington’s delegation. Thank you all that stopped by and see you again in 2025. … And Sidera for organizing it.

CO:KNOWLABS

Know Labs

Last Close

2.62

16/09 04:00

Market Cap

34.17M

Beta: -

Volume Today

409.44K

Avg: -